target earli follow fda meet
messag report financi result provid pipelin updat
guid sacituzumab bla re-submiss earli complet type
fda meet last week potenti sacituzumab label expans activ remain
track phase trial breast cancer initi
ascent enrol complet tnbc guid june trophi bladder cancer
still track enrol complet year-end updat estim maintain buy
sacituzumab bla re-submiss target earli follow two fda meet
note two separ type meet fda one routin discuss
regard clinic updat one meet discuss issu rais complet
respons letter receiv januari receiv clariti regulatori
agenc plan resubmit biolog licens applic bla earli
seek acceler approv sacituzumab govitecan treatment patient
mtnbc receiv two prior therapi metastat diseas prior
clinic meet fda agre upon content safeti updat
resubmiss standard resubmiss accord manag
sacituzumab label expans activ remain track number pivot studi
on-going phase ascend studi evalu sacituzumab mtnbc patient
least two prior treatment management guid today call patient enrol
expect complet end june studi overal surviv endpoint
aim european file manag yet guid time potenti
announc top-lin result phase studi recent
launch evalu sacituzumab mbc studi plan enrol
patient interim analysi orr dor could support potenti
acceler approv submiss pivot trophi phase trial metastat
urotheli cancer muc continu enrol patient interim analysi plan
addit phase enrich basket studi plan start
sacituzumab also evalu combin rubraca mtnbc
muc imfinzi azn mtnbc muc non-smal cell lung cancer nsclc
sg expens compani cash equival guidanc
cash runway reiter management
page analyst certif import disclosur
valuat risk
valu per share use dcf base valuat method valuat
includ lead product candid sacituzumab govitecan patient tnbc muc
breast cancer use discount rate consist commerci stage biotech
compani coverag termin growth rate appli termin year
post-assum sacituzumab biosimilar entri
risk valuat includ regulatori commerci setback potenti
emerg new competitor /or lower product sale expect risk
intellectu properti risk manag execut misstep
page analyst certif import disclosur
total cost expens
total expens incom
guggenheim secur llc estim sec file
page analyst certif import disclosur
licens fee revenu
research develop
total expens incom
net incom tax
net loss attribut non-controlling interest
guggenheim secur llc estim sec file
page analyst certif import disclosur
